Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Trends Mol Med. 2012 May 25;18(6):328–336. doi: 10.1016/j.molmed.2012.04.007

Table 1.

Differential for non-infectious Tropical malabsorption

Environmental Enteropathy Tropical Sprue Celiac Sprue Crohn’s Disease
Characteristic signs and symptoms Subclinical; can have mild malabsorption and be associated with growth faltering Chronic diarrhea, weight loss, manifestations of nutritional deficiencies A minority of patients have the classic diarrhea- predominant form; more patients have “silent” disease, characterized by lack of symptoms or extraintestinal symptoms, such as arthritis, infertility, anemia, and osteoporosis Perianal abscesses, intestinal fistulas, and strictures; individuals are at increased risk for PSC, ankylosing spondylsis, and psoriasis
Histopathology Blunting of intestinal villi, increased crypt lengthening, intraepithelial lymphocytes and lymphocytic infiltration of the lamina propria Blunting of intestinal villi, increased crypt lengthening, increased mononuclear inflammatory cells and intraepithelial lymphocytes. *indistinguishable from EE Active and chronic inflammation, variable distortion to villous architecture, metaplastic epithelial changes, possible granulomas
Serologic diagnosis No established biochemical parameters for diagnosis No established biochemical parameters for diagnosis Anti-tissue transglutaminse antibody; anti- endomysial antibody; anti- gliadin Ab (nonspecific) No established biochemical parameters for diagnosis
Etiology Recurrent environmental exposure to fecal contamination Infectious Genetic predisposition with presence of HLA-DQ2 or HLA- DQ8 initiated by exposure to gluten proteins. Pathogenesis due to both t-cell and antibody- mediated response. Unknown; genetic predisposition to certain forms of the disease, involving NOD2 and autophagy gene (ATG161L).
Available treatment None May respond to tetracycline therapy Avoidance of gluten in diet Corticosteroids and immunomodulating drugs
Refs 2 2,63 32, 80 64